Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis

Ronald J. Bernardi, Lisa Bomgaars, Elizabeth Fox, Frank M. Balis, Merrill J. Egorin, Theodore F. Lagattuta, Alberta Aikin, Patricia Whitcomb, Jamie Renbarger, Frank S. Lieberman, Stacey L. Berg, Susan M. Blaney

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Purpose: A phase I study of intrathecal (IT) gemcitabine was performed to define a safe dose and characterize the toxicity profile and CSF pharmacokinetics of gemcitabine and its major metabolite 2′,2′- difluoro-deoxyuridine (dFdU) in patients 3 years of age and older with neoplastic meningitis. Experimental design: Gemcitabine was administered via Ommaya reservoir or lumbar puncture at three dose levels: 5 mg weekly, 5 mg twice-weekly, and 10 mg twice-weekly using a standard phase I dose escalation design. Serial CSF samples were obtained for pharmacokinetic studies in seven patients with Ommaya reservoirs. Serial blood samples for pharmacokinetic studies were also obtained from three patients. Results: Ten patients were enrolled in this study. Significant neurological toxicities occurred in two patients including myelitis in a patient at the 5 mg twice-weekly dose level and somnolence in a patient at the 10 mg twice-weekly dose level. No complete responses were seen; however, three patients had stable disease. Gemcitabine was rapidly eliminated from the CSF with a terminal half-life of 61 ± 50 min. No gemcitabine or dFdU was detected in plasma. Conclusions: IT gemcitabine was associated with significant neurotoxicity; therefore, its further development for IT use is not recommended.

Original languageEnglish
Pages (from-to)355-361
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume62
Issue number2
DOIs
StatePublished - Jul 2008

Fingerprint

gemcitabine
Clinical Trials, Phase I
Meningitis
Pharmacokinetics
Deoxyuridine
Toxicity
Metabolites
Myelitis
Design of experiments
Spinal Puncture
Blood
Half-Life
Plasmas

Keywords

  • Gemcitabine
  • Intrathecal
  • Pharmacokinetic
  • Phase I

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Bernardi, R. J., Bomgaars, L., Fox, E., Balis, F. M., Egorin, M. J., Lagattuta, T. F., ... Blaney, S. M. (2008). Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. Cancer Chemotherapy and Pharmacology, 62(2), 355-361. https://doi.org/10.1007/s00280-007-0601-x

Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. / Bernardi, Ronald J.; Bomgaars, Lisa; Fox, Elizabeth; Balis, Frank M.; Egorin, Merrill J.; Lagattuta, Theodore F.; Aikin, Alberta; Whitcomb, Patricia; Renbarger, Jamie; Lieberman, Frank S.; Berg, Stacey L.; Blaney, Susan M.

In: Cancer Chemotherapy and Pharmacology, Vol. 62, No. 2, 07.2008, p. 355-361.

Research output: Contribution to journalArticle

Bernardi, RJ, Bomgaars, L, Fox, E, Balis, FM, Egorin, MJ, Lagattuta, TF, Aikin, A, Whitcomb, P, Renbarger, J, Lieberman, FS, Berg, SL & Blaney, SM 2008, 'Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis', Cancer Chemotherapy and Pharmacology, vol. 62, no. 2, pp. 355-361. https://doi.org/10.1007/s00280-007-0601-x
Bernardi, Ronald J. ; Bomgaars, Lisa ; Fox, Elizabeth ; Balis, Frank M. ; Egorin, Merrill J. ; Lagattuta, Theodore F. ; Aikin, Alberta ; Whitcomb, Patricia ; Renbarger, Jamie ; Lieberman, Frank S. ; Berg, Stacey L. ; Blaney, Susan M. / Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. In: Cancer Chemotherapy and Pharmacology. 2008 ; Vol. 62, No. 2. pp. 355-361.
@article{8f502503a411437183ecd47ad6d24289,
title = "Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis",
abstract = "Purpose: A phase I study of intrathecal (IT) gemcitabine was performed to define a safe dose and characterize the toxicity profile and CSF pharmacokinetics of gemcitabine and its major metabolite 2′,2′- difluoro-deoxyuridine (dFdU) in patients 3 years of age and older with neoplastic meningitis. Experimental design: Gemcitabine was administered via Ommaya reservoir or lumbar puncture at three dose levels: 5 mg weekly, 5 mg twice-weekly, and 10 mg twice-weekly using a standard phase I dose escalation design. Serial CSF samples were obtained for pharmacokinetic studies in seven patients with Ommaya reservoirs. Serial blood samples for pharmacokinetic studies were also obtained from three patients. Results: Ten patients were enrolled in this study. Significant neurological toxicities occurred in two patients including myelitis in a patient at the 5 mg twice-weekly dose level and somnolence in a patient at the 10 mg twice-weekly dose level. No complete responses were seen; however, three patients had stable disease. Gemcitabine was rapidly eliminated from the CSF with a terminal half-life of 61 ± 50 min. No gemcitabine or dFdU was detected in plasma. Conclusions: IT gemcitabine was associated with significant neurotoxicity; therefore, its further development for IT use is not recommended.",
keywords = "Gemcitabine, Intrathecal, Pharmacokinetic, Phase I",
author = "Bernardi, {Ronald J.} and Lisa Bomgaars and Elizabeth Fox and Balis, {Frank M.} and Egorin, {Merrill J.} and Lagattuta, {Theodore F.} and Alberta Aikin and Patricia Whitcomb and Jamie Renbarger and Lieberman, {Frank S.} and Berg, {Stacey L.} and Blaney, {Susan M.}",
year = "2008",
month = "7",
doi = "10.1007/s00280-007-0601-x",
language = "English",
volume = "62",
pages = "355--361",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis

AU - Bernardi, Ronald J.

AU - Bomgaars, Lisa

AU - Fox, Elizabeth

AU - Balis, Frank M.

AU - Egorin, Merrill J.

AU - Lagattuta, Theodore F.

AU - Aikin, Alberta

AU - Whitcomb, Patricia

AU - Renbarger, Jamie

AU - Lieberman, Frank S.

AU - Berg, Stacey L.

AU - Blaney, Susan M.

PY - 2008/7

Y1 - 2008/7

N2 - Purpose: A phase I study of intrathecal (IT) gemcitabine was performed to define a safe dose and characterize the toxicity profile and CSF pharmacokinetics of gemcitabine and its major metabolite 2′,2′- difluoro-deoxyuridine (dFdU) in patients 3 years of age and older with neoplastic meningitis. Experimental design: Gemcitabine was administered via Ommaya reservoir or lumbar puncture at three dose levels: 5 mg weekly, 5 mg twice-weekly, and 10 mg twice-weekly using a standard phase I dose escalation design. Serial CSF samples were obtained for pharmacokinetic studies in seven patients with Ommaya reservoirs. Serial blood samples for pharmacokinetic studies were also obtained from three patients. Results: Ten patients were enrolled in this study. Significant neurological toxicities occurred in two patients including myelitis in a patient at the 5 mg twice-weekly dose level and somnolence in a patient at the 10 mg twice-weekly dose level. No complete responses were seen; however, three patients had stable disease. Gemcitabine was rapidly eliminated from the CSF with a terminal half-life of 61 ± 50 min. No gemcitabine or dFdU was detected in plasma. Conclusions: IT gemcitabine was associated with significant neurotoxicity; therefore, its further development for IT use is not recommended.

AB - Purpose: A phase I study of intrathecal (IT) gemcitabine was performed to define a safe dose and characterize the toxicity profile and CSF pharmacokinetics of gemcitabine and its major metabolite 2′,2′- difluoro-deoxyuridine (dFdU) in patients 3 years of age and older with neoplastic meningitis. Experimental design: Gemcitabine was administered via Ommaya reservoir or lumbar puncture at three dose levels: 5 mg weekly, 5 mg twice-weekly, and 10 mg twice-weekly using a standard phase I dose escalation design. Serial CSF samples were obtained for pharmacokinetic studies in seven patients with Ommaya reservoirs. Serial blood samples for pharmacokinetic studies were also obtained from three patients. Results: Ten patients were enrolled in this study. Significant neurological toxicities occurred in two patients including myelitis in a patient at the 5 mg twice-weekly dose level and somnolence in a patient at the 10 mg twice-weekly dose level. No complete responses were seen; however, three patients had stable disease. Gemcitabine was rapidly eliminated from the CSF with a terminal half-life of 61 ± 50 min. No gemcitabine or dFdU was detected in plasma. Conclusions: IT gemcitabine was associated with significant neurotoxicity; therefore, its further development for IT use is not recommended.

KW - Gemcitabine

KW - Intrathecal

KW - Pharmacokinetic

KW - Phase I

UR - http://www.scopus.com/inward/record.url?scp=43749103393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43749103393&partnerID=8YFLogxK

U2 - 10.1007/s00280-007-0601-x

DO - 10.1007/s00280-007-0601-x

M3 - Article

C2 - 17909804

AN - SCOPUS:43749103393

VL - 62

SP - 355

EP - 361

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -